德谷胰岛素利拉鲁肽注射液治疗2型糖尿病患者的药物经济学研究系统评价

Pharmacoeconomic Evaluation of Insulin Degludec/Liraglutide(IDegLira) in the Treatment of Type 2 Diabetes Patients:A Systematic Review

目的 系统评价德谷胰岛素利拉鲁肽注射液(IDegLira)治疗2型糖尿病(T2DM)患者的经济性,为中国相关研究、卫生决策提供参考。方法 计算机检索中国期刊全文数据库、万方数据知识服务平台、中文期刊全文数据库、PubMed、Web of Science和Embase数据库。根据纳入、排除标准筛选文献,对符合纳入标准的文献利用卫生经济学评价报告标准共识(CHEERS)量表进行质量评价,并对文献中报告的结果进行总结。结果 最终纳入20篇英文文献,美国、英国、瑞典、意大利、捷克、荷兰、斯洛伐克和西班牙的研究结果显示,IDegLira相比基础胰岛素、基础+餐时胰岛素方案、甘精胰岛素增加剂量或基础胰岛素联合胰高糖素样肽-1受体激动剂(GLP-1RA)均具有经济性。结论 基于国外人群的药物经济学研究结果表明,IDegLira治疗血糖控制不佳的T2DM患者显示出较好的经济性。

Objective To systematically review the economy of Insulin Degludec/Liraglutide(IDegLira) in the treatment of type 2 Diabetes mellitus patients,and provide reference for relevant research and health decision-making in China.Methods PubMed,Web of Science,Embase,CNKI,WanFang Data and VIP databases were searched.The literatures meeting the inclusion criteria were evaluated by using the health economic evaluation reporting standards(CHEERS),and the results reported in the literatures were summarized.Results 20 literatures were included,all of which were English manuscripts.The research results based on the settings of the United States,Britain,Sweden,Italy,the Czech Republic,the Netherlands,Slovakia and Spain show that IDegLira is economical compared with basal insulin,basal-bolus therapy,up-titration insulin Glargine or basal insulin plus GLP-1RA.Conclusion The results of most of pharmacoeconomic studies based on foreign populations suggest that IDegLira shows a good economy in the treatment of uncontrolled T2DM.